Study Evaluating Tolerability and Anti-tumour activity of OPB 111001

• Research type

  Research Study

• Full title

  A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive to Standard Anticancer Treatment

• IRAS ID

  135671

• Contact name

  Jonathan Waxman

• Contact email

  j.waxman@imperial.ac.uk

• Sponsor organisation

  Otsuka Novel Products GmbH

• Eudract number

  2013-001249-15

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  13/LO/1332

• Date of REC Opinion

  7 Nov 2013

• REC opinion

  Further Information Favourable Opinion